Skip to content

Study · Non-randomized trial · 2004

2 results

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA

BJU international1 May 2004Cited by 90 (Europe PMC)

PMID15142146 (opens in a new tab)DOI10.1111/j.1464-410x.2004.04763.x (opens in a new tab)PepBankPUB-15142146
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In men with prostate cancer, there was evidence of an adverse effect of goserelin on cognitive function compared with before treatment.

    In plain wordsIn men with prostate cancer, there was evidence that cognitive function worsened with goserelin compared with before treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseCognitive function
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment there was evidence of an adverse effect of leuprorelin, goserelin, and CPA on cognitive function.
    2 context sentences
    Summary · context
    Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring.
    Summary · context
    In a repeated-measures design, men were assessed before treatment (baseline) and after 6 and 12 months of treatment.
  2. 02HumanNon-randomized trialSafety outcome

    In men with prostate cancer, there was evidence of an adverse effect of leuprorelin on cognitive function compared with before treatment.

    In plain wordsIn men with prostate cancer, there was evidence that cognitive function worsened with leuprorelin compared with before treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseCognitive function
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment there was evidence of an adverse effect of leuprorelin, goserelin, and CPA on cognitive function.
    2 context sentences
    Summary · context
    Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring.
    Summary · context
    In a repeated-measures design, men were assessed before treatment (baseline) and after 6 and 12 months of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.